Eloralintide, a selective, long‐acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept
Authors' conclusion
Eloralintide once weekly was well tolerated with minimal gastrointestinal adverse events and resulted in clinically meaningful weight loss.
Study context
- Population
- Participants with obesity or overweight, 3 centres in the United States; mean age 44 years, 29% female, mean BMI 32.6 kg/m²
- Participants
- 100 participants5 dose cohorts
- Comparison
- Once-weekly subcutaneous eloralintide vs placebo
- Primary endpoint
- Safety, tolerability, pharmacokinetics and pharmacodynamic profiles
- Follow-up
- 12 weeks
Methodological detailsPhase 1, placebo-controlled, participant- and investigator-blinded, multiple ascending dose, no dose escalation, three centres, 30 March 2022 to 25 January 2024
- Phase 1
- Placebo-controlled
- Participant- and investigator-blinded
- Multiple ascending dose
- No dose escalation
- Three centres
- 30 March 2022 to 25 January 2024
Primary result
As reported in the abstract
Pharmacokinetics: AUCτ,ss and Cmax · Week 12
AUCτ,ss and Cmax dose proportional; ratio of dose-normalised geometric means, AUCτ,ss
1.1
Ratio of dose-normalised geometric means, Cmax
1.0
Further findings
Percent reduction in body weight (least squares mean), across eloralintide dose groups · Week 12
- LS mean % reduction in body weight with eloralintide, range across dose groups
- 2.6% to 11.3%
Deaths and serious AEs
- Deaths
- 0
- Serious AE (6 mg eloralintide cohort), unrelated to eloralintide
- 1
Safety
Most common treatment-emergent adverse events (TEAEs) with eloralintide
- Decreased appetite
- 19%
- Headache
- 12%
- Fatigue
- 11%
- COVID-19
- 11%
- Most TEAEs mild in severity
Gastrointestinal AEs with eloralintide (infrequent)
- Diarrhoea
- 10%
- Nausea
- 8%
- Vomiting
- 4%
Original publication
Eloralintide, a selective, long‐acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes Obes Metab. Published 20 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →